E-ISSN: 1308-5263
Turk J Hematol. 2025; 42(4): 337-341 | DOI: 10.4274/tjh.galenos.2025.2025.0216
2University of Kansas Medical Center, Plasma Cell Disorder Program, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, United States
3PD Hinduja National Hospital and Medical Research Centre, Department of Medical Oncology and Cellular Therapy, Mumbai, India
4Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Department of Hematopathology, Navi Mumbai, India
5Specialty Surgical Oncology Hospital, Department of Oncosurgery, Ghatkopar, India
6YB Chavan College of Pharmacy, Department of Pharmaceutics, Aurangabad, India
Keywords: Multiple myeloma, Secondary plasma cell leukemia, BCMA CAR T, Teclistamab
2University of Kansas Medical Center, Plasma Cell Disorder Program, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, United States
3PD Hinduja National Hospital and Medical Research Centre, Department of Medical Oncology and Cellular Therapy, Mumbai, India
4Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Department of Hematopathology, Navi Mumbai, India
5Specialty Surgical Oncology Hospital, Department of Oncosurgery, Ghatkopar, India
6YB Chavan College of Pharmacy, Department of Pharmaceutics, Aurangabad, India
Anahtar Kelimeler: Multipl miyelom, Sekonder plazma hücreli lösemi, BCMA CAR T, Teclistamab
Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Following BCMA CAR T Failure
Bilal Kazi1, Al-Ola A. Abdallah2, Vijay Patil3, Prashant Tembhare4, Imaan Rumani5, Marzooka Nazim Chishti Kazi61PD Hinduja National Hospital and Medical Research Centre, Bone Marrow Transplantation, and Cellular Therapy, Department of Hematology, Mumbai, India2University of Kansas Medical Center, Plasma Cell Disorder Program, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, United States
3PD Hinduja National Hospital and Medical Research Centre, Department of Medical Oncology and Cellular Therapy, Mumbai, India
4Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Department of Hematopathology, Navi Mumbai, India
5Specialty Surgical Oncology Hospital, Department of Oncosurgery, Ghatkopar, India
6YB Chavan College of Pharmacy, Department of Pharmaceutics, Aurangabad, India
Keywords: Multiple myeloma, Secondary plasma cell leukemia, BCMA CAR T, Teclistamab
Tüm Zorluklara Rağmen: BCMA CAR T Tedavisi Başarısızlığını Takiben Sekonder Plazma Hücreli Lösemiye Dönüşen, Ultra Yüksek Riskli Nüks/Refrakter Multipl Miyelom Olgusunda Teclistamab ile Başarılı Kurtarma Tedavisi
Bilal Kazi1, Al-Ola A. Abdallah2, Vijay Patil3, Prashant Tembhare4, Imaan Rumani5, Marzooka Nazim Chishti Kazi61PD Hinduja National Hospital and Medical Research Centre, Bone Marrow Transplantation, and Cellular Therapy, Department of Hematology, Mumbai, India2University of Kansas Medical Center, Plasma Cell Disorder Program, Division of Hematologic Malignancies & Cellular Therapeutics, Kansas City, United States
3PD Hinduja National Hospital and Medical Research Centre, Department of Medical Oncology and Cellular Therapy, Mumbai, India
4Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Department of Hematopathology, Navi Mumbai, India
5Specialty Surgical Oncology Hospital, Department of Oncosurgery, Ghatkopar, India
6YB Chavan College of Pharmacy, Department of Pharmaceutics, Aurangabad, India
Anahtar Kelimeler: Multipl miyelom, Sekonder plazma hücreli lösemi, BCMA CAR T, Teclistamab
Corresponding Author: Bilal Kazi
Manuscript Language: English
Manuscript Language: English
Copyright © 2025 Turkish Journal of Hematology